Effects of Spermidine Supplementation on Cognition and Biomarkers in Older Adults With Subjective Cognitive Decline: A Randomized Clinical Trial
Schwarz C, Benson GS, Horn N, Wurdack K
Published in JAMA Network Open
Methodology
12-month randomized, double-masked, placebo-controlled phase 2b trial of wheat-germ spermidine 0.9 mg/day versus microcrystalline cellulose placebo
Key Findings
No significant change in memory performance or biomarkers over 12 months; exploratory analyses hinted at effects on inflammation and verbal memory.
Conclusions
Longer-term spermidine supplementation did not modify memory or biomarkers versus placebo.
Limitations
Low spermidine dose may have been insufficient, single centre, at-risk but non-demented population, exploratory findings unconfirmed.
Supplements Studied
longer-term spermidine supplementation in participants with subjective cognitive decline did not modify memory and biomarkers compared with placebo
Outcomes Measured
Over 12 months, no significant changes were observed in mnemonic discrimination performance (between-group difference, -0.03; 95% CI, -0.11 to 0.05; P = .47) and secondary outcomes.
Study Details
Access Study
Disclosures
Funding
Academic/non-industry research support
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.